SkinCeuticals | Discoloration Defense Corrective Serum (30ml)

SkinCeuticals' Discoloration Defense is clinically proven to reduce the appearance of dark spots and discoloration on the face. Powered by kojic acid, tranexamic acid, and vitamin B3, this advanced formula is a hydroquinone-free skin brightening serum.

Clinical Studies:
In a 12-week clinical study*, Discoloration Defense significantly improved the appearance of key skin discoloration markers on Fitzpatrick I-IV skin tones:

• 60% average improvement in the appearance of stubborn brown patches
• 59% average improvement in the appearance of skin discoloration
• 81% average improvement in the appearance of post-acne marks
• 59% average improvement in the appearance of even skin tone

In a 12-week study** on deeper skin tones (Fitzpatrick V-VI), twice-daily application of Discoloration Defense demonstrated a statistically-significant improvement in the appearance of discoloration, post-inflammatory discoloration, and even skin tone:

• 33% reduction in hyperpigmentation at 12 weeks
• 34% reduction in post-inflammatory hyperpigmentation at 12 weeks

CLINICALLY PROVEN RESULTS
Individual results at 12 weeks.


Protocol:
12-week, clinical study, 63 subjects. Discoloration Defense Serum was applied to the face twice a day in conjunction with a sunscreen

*A 12-week, single-center, clinical study was conducted on 50 females, ages 25 to 60, Fitzpatrick I-IV, with mild-to-moderate facial skin discoloration, including stubborn dark spots, post-acne marks and uneven skin tone. Discoloration Defense was applied to the face twice a day in conjunction with a sunscreen. Efficacy and tolerability evaluations were conducted at baseline and at weeks 2, 4, 8, and 12.

**A 12-week, single-center, clinical study was conducted on 51 female subjects, Fitzpatrick V-VI, with visible signs of skin discoloration/hyperpigmentation, including post-inflammatory hyperpigmentation and melasma. Discoloration Defense was applied to the face twice a day in conjunction with a sunscreen. Efficacy and tolerability evaluations were conducted at baseline and at weeks 2, 4, 8, and 12.